English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/94985
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Título

New approaches & technologies of venomics to meet the challenge of human envenoming by snakebites in India

AutorWarrell, David A.; Gutiérrez, José María; Calvete, Juan J. ; Williams, David
Palabras claveAntivenoms
Cobra
Envenoming
krait
Preclinical efficacy
Russell’s viper
Snakebite
Venom
Venomics
Fecha de publicación6-ago-2013
EditorIndian Council of Medical Research
CitaciónIndian Journal of Medical Research;138:38-59 (2013)
ResumenThe direct estimate of 46,000 snakebite deaths in India in 2005 (1 for every 2 HIV/AIDS deaths), based on verbal autopsies, renders unrealistic the total of only 47,000 snakebite deaths in the whole world in 2010, obtained indirectly as part of the "Global Burden of Disease 2010" study. Persistent underestimation of its true morbidity and mortality has made snakebite the most neglected of all the WHO's "neglected tropical diseases", downgrading its public health importance. Strategies to address this neglect should include the improvement of antivenom, the only specific antidote to envenoming. To accommodate increased understanding of geographical intraspecific variation in venom composition and the range of snake species that are medically important in India, the design of antivenoms (choice of venom sources and species coverage) should be reconsidered. Methods of preclinical and clinical testing should be improved. The relatively new science of venomics involves techniques and strategies for assessing the toxin composition of snake venoms directly through proteomics-centred approaches or indirectly via high-throughput venom gland transcriptomics and bioinformatic analysis. Antivenomics is translational venomics: a proteomics-based protocol to quantify the extent of cross-reactivity of antivenoms against homologous and heterologous venoms. These approaches could revolutionize the preclinical assessment of antivenom efficacy, leading to a new generation of antivenoms that are clinically more effective
Descripción22 páginas, 8 figuras.
Versión del editorhttp://www.ijmr.org.in/text.asp?2013/138/1/38/116180
URIhttp://hdl.handle.net/10261/94985
ISSN0971-5916
E-ISSN0975-9174
Aparece en las colecciones: (IBV) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
2013 Indian J Med Res 138-00138.pdf8,55 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.